Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Wwww.x-o.co.uk
5.95 to trade. Been with them for years never had a problem
The best we can do with the available data is read it and accept it as representative of where we are right now. Wait for further information . My table was an extract from the recent RNS . Others can make up their mind on what they think of your 37 letters comment.
Brilliant thanks for clarifying that. That being the case I would say the £1 bounce is a very conservative guess. More like £10 I would say. Great news for me and the patients. Let's hope your analysis is not misleading.
In summary, the data so far gives me confidence this works and I would expect to see a mean value for the 9-month datas, once more samples are in, of about 37 letters
=======================================================================================================
For clarity are you saying you expect a mean improvement of 7 lines in the ETDRS chart?
ah Thanks for that. Once everyone has read your post the £1 the share has lost should bounce straight back up.
Slowing down the rate of shareholder value degradation might be an idea as well. This is looking like a 2 decade investment now.
Clinically meaningful is 3 lines or 15 letters on the ETDRS chart.
Month 1 = +14.5 letters (mean)
month 2 = +13 letters (mean)
month 3 = +17.8 letters (mean)
month 6 = +28.7 letters(mean)
month 9 = +12letters (mean).
Sweet spot appears to be months 3-6(ish) for clinically meaningful data. Falls below clinically meaningful at month 9.
Alliance News) - ReNeuron Group PLC on Wednesday posted positive results from early patients in its ongoing trial of a treatment for retinitis pigmentosa, which causes blindness, but was less profound in later patients.
Shares in ReNeuron were down 20% at 215.70 pence in London in afternoon trading.
The efficacy of treatment in the first three patients enrolled in the phase 2a segment of the study "was rapid and profound" but in subsequent patients efficacy was seen "at a lower rate and magnitude". The total extent of improvement isn't yet known, since the study is still ongoing.
The phase 1/2a clinical trial is assessing ReNeuron's "human retinal progenitor cell (hRPC) therapy candidate". Reneuron said that the improvements in visual acuity so far, as measured by the number of letters read on an eye chart, have been "a clear signal of efficacy".
This was considered to be particularly the case given that RP, which covers a number of conditions that interfere with the retina at the back of the eye, typically worsens over time. Usually, patients have trouble with their peripheral vision and with seeing in the dark, but central vision can also be damaged.
So far 22 patients have been treated in the phase 1/2a study and none experienced "product-related serious adverse events", although two suffered loss of vision relating to the surgical procedure.
Excluding those patients with surgery-related vision loss, at 1 month post-treatment, mean improvement in visual acuity from the treated eye was an additional 14.5 letters, compared to 1.6 letters in the untreated eye. By 6 months, the mean improvement in the treated eye was 28.7 letters versus 7.8 letters in the untreated eye.
However, at 9 months, the mean improvement was 12.0 letters in the treated eye, while the untreated eye did not experience improvement but instead lost 1.0 letters.
ReNeuron Chief Executive Olav Hellebo said: "We are greatly encouraged by the latest efficacy data from the ongoing phase 1/2a clinical study of our hRPC cell therapy candidate in patients with RP. It is especially gratifying to see positive data given the inherent challenge in addressing a disease as complex as RP and we look forward to further progressing the clinical development of this promising cell therapy candidate."
By Anna Farley; annafarley@alliancenews.com
Ignore director buys. Half the time its a ruse.
It's time for RENE to delivery the goods. Shareholders I think will have had enough of this buy now. Over a decade of RNS with varying degrees of hope and a lot of tapping up for additional funds.
RENE is not a charity it's supposed to deliver return for shareholders at some stage. I think that stage is roundabout now.
but my view if the results didn't have any potential this would of tanked a lot faster
============================================================================
£1.20 fall in a day is not bad. What you looking for?
Hopefully long term holders have not had their day in the sun here. Held these for over ten years and never really been in profit. Thankfully traded the rise from 50p to 300p with another tranche but the original holding has more or less always been a loser.
Yes buying because they thought market reaction was obviously going to be better to the RNS.
Jarvis had loads of buying on run up to RNS awarding major rail contract only to go into admin a week or so later.
200p-270p on no news. News out and tanks to 200p.
Looks like somebody can't be trusted to keep their mouth shut. This was going nowhere then pop big jump. Leaky ship.
With AIM stocks it is years of share price erosion then boom a few days of massive increases. The key appears to be don't believe the hype and certainly sell after a couple days of rises. Hold on too long after a spike and it turns to dust. Follow that and you will win more than loose.
Overvalued